anti-CD19 CAR T-cell therapy Lentigen (Intas Pharmaceuticals)

N/A

Report date: 2025/01/26 18:16:23

Base Information

Drug Nameanti-CD19 CAR T-cell therapy Lentigen (Intas Pharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIntas Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesIntas Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A